#United States #Newton #Myelofibrosis #Selinexor #Ruxolitinib

Karyopharm Pursues FDA Submission for Innovative Cancer Therapy

In an exciting development for patients with myelofibrosis, Karyopharm Therapeutics Inc., a leader in pioneering cancer therapies, has announced its plans to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) by August 2026. This move seeks accelerated approval of selinexor in combination with ruxolitinib, representing a significant therapeutic leap for individuals battling this rare cancer.

The sNDA submission is a culmination of fruitful dialogues with the FDA, where fruitful engagements revealed that a spleen volume reduction of 35% (SVR35) is a clinically valid surrogate marker to predict overall survival. The submission will also leverage long-term overall survival data gathered from the ongoing Phase 3 SENTRY trial, which aims to further substantiate the clinical benefits of this combination therapy.

The SENTRY trial, which remains blinded and does not allow patient crossover, has yielded some of the most compelling frontline data in the treatment of myelofibrosis to date. Dr. John Mascarenhas, an influential figure in the field and a Professor of Medicine at the Icahn School of Medicine at Mount Sinai, highlighted the trial's outcomes by saying, "The combination of selinexor and ruxolitinib demonstrated rapid, deep, and sustained responses in spleen volume, alongside promising overall survival results. There’s significant potential here to redefine the treatment landscape for myelofibrosis."

Richard Paulson, President and CEO of Karyopharm, underscored the urgency of innovation in this domain. He stated, "Patients with myelofibrosis have waited too long for meaningful advances in treatment options. Our planned sNDA submission marks both a transformative opportunity for patients and a pivotal moment in Karyopharm's journey."

Alongside the backbone data from the SENTRY trial, Karyopharm intends to request Priority Review upon submission. If granted, there would be a target action date approximately six months post-application, which would accelerate the therapy's availability to patients. This integrated therapy offers hope, as it could become the first approved combination treatment for myelofibrosis, utilizing the novel mechanism of action granted by the coupling of XPO1 and JAK inhibition.

Understanding Myelofibrosis

Myelofibrosis is characterized as a rare bone marrow cancer affecting an estimated 20,000 individuals in the United States alone. The disease causes progressive scarring in the bone marrow, subsequently leading to severe anemia and symptoms such as fatigue, splenomegaly (enlargement of the spleen), and various debilitating side effects including abdominal pain and night sweats. Currently, the only FDA-approved treatments for myelofibrosis are JAK inhibitors like ruxolitinib, underscoring the desperate need for additional therapies.

Karyopharm's XPOVIO (selinexor) has already established its groundwork in multiple oncology indications, showing significant promise as a first-in-class agent that inhibits exportin 1 (XPO1). Its ongoing exploration in myelofibrosis illustrates Karyopharm's commitment to addressing high-unmet medical needs in hematological cancers.

With hope and anticipation, both Karyopharm and the patients awaiting new therapy look toward the impending sNDA submission and its potential to bring forth a paradigm shift in the management of myelofibrosis. The landscape of cancer treatment continuously evolves, and at its forefront, companies like Karyopharm could redefine what is possible for patients facing such daunting challenges, heralding an era of transformative care.

For detailed information, interested parties are encouraged to visit Karyopharm's official website or contact their medical information department directly. Karyopharm remains dedicated to making impactful strides in the fight against cancer, with a focus on promoting patient health and access to innovative therapeutics.